ArticleBMC cancer2025
Survival benefit of conversion surgery after intravenous 5-fluorouracil-based chemotherapy in unresectable advanced gastric cancer: a retrospective cohort study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Control to Conversion: Optimizing Systemic Therapy for Curative-Intent Conversion Surgery in Metastatic Gastric Cancer.Journal of gastric cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic chemotherapy may relieve symptoms and induce tumor downstaging in patients with unresectable gastric cancer. However, the survival benefit of primary tumor resection after chemotherapy remains unclear. This study aimed to determine the survival outcomes of conversion surgery in patients with unresectable gastric cancer.
methodsThis retrospective cohort study reviewed the data of patients with unresectable advanced gastric cancer treated with systemic chemotherapy between 2005 and 2019. The primary outcome was overall survival (OS). Patient characteristics and clinicopathological stages were assessed. The rates of conversion surgery and tumor progression after conversion surgery were determined.
resultsThe study included 86 patients, of whom 26 (30.2%) responded to systemic chemotherapy and underwent conversion surgery. Most patients had a diffuse-type, poorly differentiated adenocarcinoma, a single non-curative factor, and peritoneal metastasis, if present. The leucovorin plus oxaliplatin regimen was the dominant first-line chemotherapy regimen. All patients who underwent conversion surgery achieved R0 resection. The median time to progression was 8.9 months. The median survival time was 25.8 (95% confidence interval [CI], 19.88-32.85) months in the conversion group and 10.1 (95% CI, 6.54-11.93) months in the non-conversion group (p < 0.001).
conclusionsFor patients with unresectable advanced gastric cancer who respond favorably to systemic chemotherapy, conversion surgery should be considered as a treatment option. This approach can improve OS and delay disease progression. Nonetheless, the present study could not reveal the predictors of OS besides chemotherapy resistance. Therefore, a multimodal approach combining systemic chemotherapy with conversion surgery should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.